Laboratory of Hematology, GIGA I³, University of Liège, Liège, Belgium.
Department of Hematology, CHU de Liège, Liège, Belgium.
Front Immunol. 2022 Jul 5;13:911080. doi: 10.3389/fimmu.2022.911080. eCollection 2022.
Radioimmunotherapy (RIT) is a cancer treatment that combines radiation therapy with tumor-directed monoclonal antibodies (Abs). Although RIT had been introduced for the treatment of CD20 positive non-Hodgkin lymphoma decades ago, it never found a broad clinical application. In recent years, researchers have developed theranostic agents based on Ab fragments or small Ab mimetics such as peptides, affibodies or single-chain Abs with improved tumor-targeting capacities. Theranostics combine diagnostic and therapeutic capabilities into a single pharmaceutical agent; this dual application can be easily achieved after conjugation to radionuclides. The past decade has seen a trend to increased specificity, fastened pharmacokinetics, and personalized medicine. In this review, we discuss the different strategies introduced for the noninvasive detection and treatment of hematological malignancies by radiopharmaceuticals. We also discuss the future applications of these radiotheranostic agents.
放射免疫治疗（RIT）是一种将放射疗法与肿瘤定向单克隆抗体（Abs）结合的癌症治疗方法。尽管 RIT 早在几十年前就被引入用于治疗 CD20 阳性非霍奇金淋巴瘤，但它从未得到广泛的临床应用。近年来，研究人员已经开发出基于 Ab 片段或 Ab 模拟物（如肽、affibodies 或单链 Abs）的治疗诊断试剂，这些试剂具有改善的肿瘤靶向能力。治疗诊断试剂将诊断和治疗能力结合到单个药物制剂中；这种双重应用可以通过与放射性核素缀合来轻松实现。过去十年，人们越来越关注特异性、药代动力学和个性化医疗。在这篇综述中，我们讨论了为通过放射性药物非侵入性检测和治疗血液系统恶性肿瘤而引入的不同策略。我们还讨论了这些放射治疗诊断试剂的未来应用。
